Judge chops $8 million Fosamax jaw award to $1.5 million in bellwether case
This article was originally published in Scrip
Executive Summary
A federal judge has lessened a jury award against Merck & Co won by plaintiff Shirley Bolesfrom $8 million to $1.5 million in one of the bellwether product liability cases over the company's bisphosphonate Fosamax (alendronate), but upheld the verdict despite claims by Merck that a lawyer for the plaintiff had swayed the jury vote with inflammatory and prejudicial remarks in his closing statements.